.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Baxter
Cipla
Teva
Fuji
McKinsey
McKesson
Express Scripts
Queensland Health
US Department of Justice

Generated: December 13, 2017

DrugPatentWatch Database Preview

FLOVENT HFA Drug Profile

« Back to Dashboard

Which patents cover Flovent Hfa, and what generic alternatives are available?

Flovent Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. There are fifteen patents protecting this drug.

This drug has ninety patent family members in thirty-four countries and four supplementary protection certificates in three countries.

The generic ingredient in FLOVENT HFA is fluticasone propionate. There are twenty-five drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-003May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-003May 14, 2004RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FLOVENT HFA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-003May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-001May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004► Subscribe► Subscribe
Glaxo Grp LtdFLOVENT HFAfluticasone propionateAEROSOL, METERED;INHALATION021433-002May 14, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: FLOVENT HFA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,101,534Suspension aerosol formulations► Subscribe
7,105,152Suspension aerosol formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FLOVENT HFA

Country Document Number Estimated Expiration
Israel130549► Subscribe
China1094876► Subscribe
Yugoslavia29899► Subscribe
Germany69735247► Subscribe
Australia1234297► Subscribe
New Zealand246421► Subscribe
Spain2258753► Subscribe
Canada2320129► Subscribe
Australia5762798► Subscribe
Peru6399► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLOVENT HFA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/026United Kingdom► SubscribePRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
C0067France► SubscribePRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0014France► SubscribePRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chubb
Daiichi Sankyo
Citi
Boehringer Ingelheim
Queensland Health
UBS
Moodys
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot